Trial Profile
Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs CV 8102 (Primary) ; Programmed cell death-1 receptor antagonists
- Indications Adenoid cystic carcinoma; Head and neck cancer; Malignant melanoma; Skin cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors CureVac
- 03 Nov 2021 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2021 Preliminary results from the completed dose escalation part presented at the 46th European Society for Medical Oncology Congress
- 16 Aug 2021 According to a CureVac media release, the company expects to updates on the progress of this study at the European Society for Medical Oncology (ESMO) congress and the Society for Immunotherapy of Cancer (SITC) annual meeting later this year.